secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001438533-25-000012
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere submits sNDA to FDA seeking priority review for FILSPARI in FSGS
------------------------------------------------------------------------

- Submitted sNDA on March 17, 2025 seeking priority review for traditional approval of FILSPARI (sparsentan) for FSGS.
- Supported by Phase 3 DUPLEX study (interim FPRE endpoint met; primary eGFR slope missed) and Phase 2 DUET study (met primary endpoint).
- FDA has 60 days to decide on acceptance; company expects notice in Q2 2025.
- If approved, FILSPARI would be first FDA-approved therapy for FSGS, affecting >40,000 US patients.
- No currently approved pharmacologic therapies for FSGS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000012/0001438533-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000012/tvtx-20250317.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer